Skip to main content
SpringerLink
Log in

Pharmacokinetics of oxaprozin in women receiving conjugated estrogen

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The kinetics of a single 1200 mg oral dose of oxaprozin, a nonsteroidal antiinflammatory agent of the propionic acid class, was studied in 22 healthy female volunteers aged 21 to 64 years. Eleven subjects had been taking a conjugated estrogen preparation for at least 3 months; the other 11 subjects served as control women who were not taking conjugated estrogens.

Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.11; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 µg/ml, respectively. None of the differences were significant. However, the time of peak concentration (8.9 vs 4.0 h) was significantly longer in the control group than in the conjugated estrogen group, respectively (p<0.05).

Oxaprozin clearance, accomplished by a combination of oxidation and conjugation, is unimpaired by coadministration of conjugated estrogens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moskowitz RW (ed) (1986) Oxaprozin: a new nonsteroidal antiinflammatory drug. Semin Arthritis Rheum 15 [Suppl 2]: 1–107

  2. Lewis AJ, Carlson RP, Chang J, Gilman SC, Nielsen S, Rosenthale ME, Janssen FW, Ruelius HW (1983) The pharmacological profile of oxaprozin, an antiinflammatory and analgesic agent with low gastrointestinal toxicity. Curr Ther Res 34: 777–794

    Google Scholar 

  3. Greenblatt DJ, Scavone JM (1986) Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. Semin Arthritis Rheum 15 [Suppl 3]: 18–26

    Google Scholar 

  4. Janssen FW, Chiang ST, Walker BR, Ruelius HW (1984) Disposition of oxaprozin in healthy subjects and certain disease states. Curr Ther Res 35: 363–376

    Google Scholar 

  5. Janssen FW, Jusko WJ, Chiang ST, Kirkman SK, Southgate PJ, Coleman AJ, Ruelius HW (1980) Metabolism and kinetics of oxaprozin in normal subjects. Clin Pharmacol Ther 27: 352–362

    Google Scholar 

  6. Chiang ST, Lasseter KE, Fluck ER, Janssen FW, Leelavathi D, Hubsher JA (1984) Oxaprozin dose proportinality. J Clin Pharmacol 24: 515–522

    Google Scholar 

  7. Greenblatt DJ, Matlis R, Scavone JM, Blyden GT, Harmatz JS, Shader RI (1985) Oxaprozin pharmacokinetics in the elderly. Br J Clin Pharmacol 19: 373–378

    Google Scholar 

  8. Chiang ST, Morrison G, Knowles JA, Ruelius HW, Walker BR (1980) Oxaprozin disposition in renal disease. Clin Pharmacol Ther 31: 509–515

    Google Scholar 

  9. Scavone JM, Greenblatt DJ, Matlis R, Harmatz JS (1986) Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. Eur J Clin Pharmacol 31: 371–374

    Google Scholar 

  10. Abernethy DR, Greenblatt DJ (1981) Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clin Pharmacol Ther 29: 106–110

    Google Scholar 

  11. Ochs HR, Greenblatt DJ, Verburg-Ochs B, Abernethy DR, Knüchel M (1984) Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. Pharmacology 28: 188–195

    Google Scholar 

  12. Carter DE, Bressler R, Hughes MR, Haussler MR, Christian D, Heine MW (1975) Effect of oral contraceptives on plasma clearance. Clin Pharmacol Ther 18: 700–707

    Google Scholar 

  13. Homeida M, Halliwell M, Branch RA (1978) Effects of an oral contraceptive on hepatic size and antipyrine metabolism in premenopausal women. Clin Pharmacol Ther 24: 228–232

    Google Scholar 

  14. Tornatore KM, Kanarkowski R, McCarthy TL (1982) Effect of chronic oral contraceptive steroids on theophylline disposition. Eur J Clin Pharmacol 23: 129–134

    Google Scholar 

  15. Abernethy DR, Greenblatt DJ, Divoll M, Arendt R, Ochs HR, Shader RI (1982) Impairment of diazepam metabolism by low-dose estrogen oral contraceptive steroids. N Engl J Med 306: 791–792

    Google Scholar 

  16. Patwardhan RV, Desmond PV, Johnson RF, Schenker S (1980) Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med 95: 603–608

    Google Scholar 

  17. Patwardhan RV, Mitchell MC, Johnson RF, Schenker S (1983) Differential effects of oral contraceptive steroids on the metabolism of benzodiazepines. Hepatology 3: 248–253

    Google Scholar 

  18. Roberts RK, Desmond PV, Wilkinson GR, Schenker S (1979) Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives. Clin Pharmacol Ther 25: 826–831

    Google Scholar 

  19. Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB (1984) Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 36: 683–690

    Google Scholar 

  20. Matlis R, Greenblatt DJ (1984) Rapid HPLC analysis of oxaprozin, a non-steroidal antiinflammatory agent, using radial compression separation. J Chromatogr 310: 445–449

    Google Scholar 

  21. Gustavson LE, Legler UF, Benet LZ (1986) Impairment of prednisolone disposition in women taking oral contraceptives or conjugated estrogens. J Clin Endocrinol Metab 62: 234–237

    Google Scholar 

  22. El-Yousef MK (1974) Effects of conjugated estrogens on plasma butaperazine levels. Psychopharmacologia (Berl) 39: 39–41

    Google Scholar 

Download references

Author information

Author notes

  1. H. R. Ochs

    Present address: Marienkrankenhaus, Soest, Federal Republic of Germany

Authors and Affiliations

  1. Division of Clinical Pharmacology, Departments of Psychiatry and Medicine, Tufts University School of Medicine and New England Medical Center, Boston, MA, USA

    J. M. Scavone, H. R. Ochs, D. J. Greenblatt & R. Matlis

  2. the Medizinische Universitätsklinik, University of Bonn, Federal Republic Germany

    J. M. Scavone, H. R. Ochs, D. J. Greenblatt & R. Matlis

Authors
  1. J. M. Scavone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. R. Ochs
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. J. Greenblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Matlis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scavone, J.M., Ochs, H.R., Greenblatt, D.J. et al. Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. Eur J Clin Pharmacol 35, 105–108 (1988). https://doi.org/10.1007/BF00555518

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00555518

Key words

Search

Navigation